1 asset in Nodular Malignant Melanoma
Therapeutic assets addressing Nodular Malignant Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Dinaciclib Nodular Malignant Melanoma | National Cancer Institute (NCI) | P2 | CCC (53) |